Imaging agent developer ImaginAb has signed a multiyear, nonexclusive licensing agreement with pharmaceutical firm Merck.
Under the deal, Merck -- known as MSD outside of the U.S. and Canada -- will purchase ImaginAb's CD8 T-cell PET imaging agent for use in immuno-oncology clinical trials involving multiple types of cancer. Furthermore, Merck is making an equity investment in ImaginAb's series B financing round, according to ImaginAb.
